PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

Tue, 16th Jan 2024 09:14

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

----------

FTSE 100

----------

JPMorgan cuts Rightmove to 'underweight' (neutral) - price target 493 (585) pence

----------

Goldman Sachs raises Rightmove price target to 667 (659) pence - 'neutral'

----------

JPMorgan cuts HSBC price target to 660 (690) pence - 'neutral'

----------

JPMorgan cuts Standard Chartered price target to 820 (990) pence - 'overweight'

----------

Jefferies cuts Standard Chartered price target to 1,050 (1,100) pence - 'buy'

----------

JPMorgan cuts NatWest price target to 260 (280) pence - 'overweight'

----------

JPMorgan cuts Barclays price target to 180 (190) pence - 'overweight'

----------

Jefferies raises Berkeley price target to 4,706 (4,572) pence - 'hold'

----------

Jefferies raises Barratt Developments price target to 583 (470) pence - 'hold'

----------

Peel Hunt cuts Taylor Wimpey to 'hold' (add) - price target 145 (125) pence

----------

Jefferies raises Taylor Wimpey price target to 172 (143) pence - 'buy'

----------

JPMorgan raises Taylor Wimpey price target to 101 (96) pence - 'neutral'

----------

Citigroup raises Beazley price target to 723 (680) pence - 'buy'

----------

Citigroup cuts Prudential price target to 1130 (1350) pence - 'buy'

----------

UBS cuts Rentokil Initial price target to 375 (460) pence - 'sell'

----------

Goldman Sachs raises Auto Trader group price target to 886 (863) pence - 'buy'

----------

Barclays cuts Croda International target to 5,000 (6,300) pence - 'equal weight'

----------

Goldman Sachs raises WPP price target to 870 (849) pence - 'neutral'

----------

Goldman Sachs raises Informa price target to 1,027 (1,019) pence - 'buy'

----------

Goldman Sachs raises Relx price target to 3,795 (3,405) pence - 'buy'

----------

Goldman Sachs raises Pearson price target to 1,319 (1,225) pence - 'buy'

----------

Berenberg cuts Rolls-Royce to 'sell' (hold) - price target 240 (100) pence

----------

Bernstein raises Convatec price target to 305 (285) pence - 'outperform'

----------

Morgan Stanley raises AstraZeneca price target to 13,400 (12,900) pence - 'overweight'

----------

UBS cuts AstraZeneca to 'sell' (buy) - price target 10,700 (13,000) pence

----------

Morgan Stanley raises GSK price target to 1730 (1535) pence - 'equal-weight'

----------

UBS raises GSK to 'buy' (sell) - price target 1,860 (1,310) pence

----------

Citigroup raises St James's Place price target to 667 (660) pence - 'neutral'

----------

Citigroup raises Phoenix price target to 509 (501) pence - 'neutral'

----------

Citigroup raises M&G price target to 223 (208) pence - 'neutral'

----------

Citigroup raises Legal & General price target to 254 (232) pence - 'neutral'

----------

Citigroup raises Aviva price target to 450 (422) pence - 'neutral'

----------

Deutsche Bank cuts Diageo price target to 2,450 (2,470) pence - 'sell'

----------

Goldman Sachs raises Experian price target to 4,250 (4,000) pence - 'buy'

----------

FTSE 250

----------

RBC starts Premier Foods with 'outperform' - price target 180 pence

----------

Citigroup raises Hiscox price target to 1,084 (1,032) pence - 'neutral'

----------

RBC cuts PageGroup price target to 550 (560) pence - 'outperform'

----------

Barclays raises Spire Healthcare price target to 315 (305) pence - 'overweight'

----------

Berenberg raises Direct Line to 'buy' (hold) - price target 195 (170) pence

----------

Jefferies raises Redrow price target to 774 (635) pence - 'buy'

----------

Jefferies raises Vistry price target to 1,023 (831) pence - 'hold'

----------

Citigroup cuts Drax to 'sell' (buy) - price target 437 (474) pence

----------

Barclays cuts Johnson Matthey target to 2,030 (2,100) pence - 'equal weight'

----------

Goldman Sachs cuts ITV to 'sell' (neutral) - price target 60 (67) pence

----------

Jefferies raises Persimmon to 'buy' (hold) - price target 1,706 (1,181) pence

----------

Jefferies cuts Crest Nicholson to 'hold' (buy) - price target 234 (331) pence

----------

Jefferies raises Bellway price target to 3,301 (2,827) pence - 'buy'

----------

Jefferies cuts Moneysupermarket.com to 'hold' (buy) - price target 265 (305) pence

----------

JPMorgan raises Ashmore price target to 185 (183) pence - 'underweight'

----------

SMALL CAP

----------

Numis cuts Wise to 'hold' (buy) - price target 950 pence

----------

Morgan Stanley raises Wise price target to 1,070 (1,050) pence - 'overweight'

----------

Goldman Sachs raises Wise price target to 1,250 (1,200) pence - 'buy'

----------

Goldman Sachs raises Wise price target to 1,250 (1,200) pence - 'buy'

----------

UBS cuts Card Factory price target to 107 (109) pence - 'neutral'

----------

investec cuts Reach to 'hold' (buy) - price target 70 (100) pence

----------

Peel Hunt raises Oxford Nanopore to 'reduce' (sell) - price target 155 pence

----------

Barclays raises Synthomer price target to 416 (187) pence - 'equal weight'

----------

JPMorgan cuts Bank of Ireland to 'underweight' (neutral) - price target 8 (10.80) EUR

----------

JPMorgan cuts AIB price target to 4.80 (5.80) EUR - 'overweight'

----------

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.